The MMRC and Multiple Myeloma Research Foundation (MMRF) were recently featured on NBC Nightly News. The segment highlights the strides the two organizations have made in advancing research and breaking down barriers to drug development in the field of myeloma. Click here to watch the video.

The MMRC, in collaboration with Genentech, has initiated an innovative antibody screening project to identify antigens expressed on myeloma cells that may represent promising therapeutic targets for monoclonal antibodies and to identify promising monoclonal antibodies that may be further investigated in future studies. These studies, led by Leif Bergsagel, MD, Associate Professor of Medicine at the Mayo Clinic in Scottsdale, Ariz., will be conducted within the MMRC's Validation Core. "Monoclonal antibodies are an exciting potential class of drugs that may be effective in treating myeloma," said William Dalton, PhD, MD, Chief Executive Officer of the H. Lee Moffitt Cancer Center & Research Institute and member of MMRC Steering Committee. "These studies will serve as a preliminary screen to identify druggable targets for monocloncal antibody therapy and to potentially identify monoclonal antibodies that hold promise in treating myeloma."

The MMRC is pleased to offer a new video presentation on the MMRC' innovative model. Featuring interviews with members of the MMRC External Advisory Board, MMRC Progress Review Committee, and industry partners, this video discusses how the MMRC is rapidly removing research barriers to accelerate drug development in myeloma.